Nebula Research & Development LLC purchased a new stake in Chemed Co. (NYSE:CHE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,838 shares of the company's stock, valued at approximately $2,033,000.
Several other institutional investors have also added to or reduced their stakes in the company. Neuberger Berman Group LLC boosted its stake in Chemed by 1.2% in the 4th quarter. Neuberger Berman Group LLC now owns 501,562 shares of the company's stock valued at $265,726,000 after purchasing an additional 5,809 shares during the period. Geode Capital Management LLC boosted its stake in Chemed by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 340,409 shares of the company's stock valued at $180,654,000 after purchasing an additional 4,966 shares during the period. FMR LLC boosted its stake in Chemed by 18.9% in the 4th quarter. FMR LLC now owns 283,790 shares of the company's stock valued at $150,352,000 after purchasing an additional 45,174 shares during the period. JPMorgan Chase & Co. raised its holdings in Chemed by 8.2% in the 4th quarter. JPMorgan Chase & Co. now owns 266,786 shares of the company's stock valued at $141,343,000 after acquiring an additional 20,310 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in Chemed by 5.1% in the 4th quarter. Epoch Investment Partners Inc. now owns 252,237 shares of the company's stock valued at $133,635,000 after acquiring an additional 12,167 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Chemed news, CEO Kevin J. Mcnamara sold 1,000 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $615.33, for a total value of $615,330.00. Following the sale, the chief executive officer now owns 101,679 shares in the company, valued at approximately $62,566,139.07. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.29% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on CHE shares. Royal Bank of Canada lifted their price objective on Chemed from $667.00 to $674.00 and gave the company an "outperform" rating in a report on Monday. StockNews.com raised Chemed from a "hold" rating to a "buy" rating in a report on Friday, March 7th.
Check Out Our Latest Stock Report on CHE
Chemed Stock Performance
Shares of Chemed stock traded up $9.58 during trading on Monday, reaching $565.32. 115,588 shares of the company's stock were exchanged, compared to its average volume of 98,797. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $623.61. The company has a market cap of $8.26 billion, a P/E ratio of 28.57, a PEG ratio of 2.15 and a beta of 0.49. The firm's 50-day moving average price is $587.84 and its 200 day moving average price is $566.56.
Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $646.94 million during the quarter, compared to analysts' expectations of $641.78 million. During the same quarter in the previous year, the firm earned $5.20 EPS. Chemed's revenue was up 9.8% on a year-over-year basis. As a group, equities research analysts predict that Chemed Co. will post 21.43 EPS for the current year.
Chemed Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Monday, February 24th were given a dividend of $0.50 per share. The ex-dividend date was Monday, February 24th. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. Chemed's dividend payout ratio is currently 9.74%.
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Articles
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
